Tokyo, Dec. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059790) titled 'Efficacy analysis of intraluminal shunt for preventing hyperperfusion following carotid endoarterectomy in patients with misery perfusion' on Dec. 15.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Historical

Primary Sponsor: Institute - Iwate Medical University

Condition: Condition - cervical carotid artery Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To evaluate if intraluminal shunt could prevent hyperperfusion following carotid endarterectomy in patients with misery perfusion. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Apllication of intraluminal shunt during carotid endoarterectomy for patients with internal carotid artery stenosis

Eligibility: Age-lower limit - 20 years-old = Gender - Male and Female Key inclusion criteria - Patients who plan to undergo carotid endoarterectomy (CEA) and meet following criteria. A)Patients who have misery perfusion on preoperative examinations and give consent.

B) Control group patients who had misery perfusion and underwent CEA without using intraluminal shunt between 2020/7/1 to 2025/6/30. Key exclusion criteria - A) 1. Patients who have thinner diameter of outer diameter of intraluminal shunt tube (3mm) 2. Patients who lack required data.

B) 1. Patients who reject to be included the study 2. Patients that intraluminal shunt could not be implanted 3. Patients who lack required data. Target Size - 30

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 11 Month 06 Day Date of IRB - 2025 Year 12 Month 12 Day Anticipated trial start date - 2025 Year 12 Month 15 Day Last follow-up date - 2029 Year 10 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068364

Disclaimer: Curated by HT Syndication.